Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -12.47% | 2.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.47% | 2.91% | |||
| Cost of Revenue | -28.15% | 10.65% | |||
| Gross Profit | 8.18% | -5.77% | |||
| SG&A Expenses | -29.71% | -29.44% | |||
| Depreciation & Amortization | 1.04% | -4.74% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -26.73% | -16.57% | |||
| Operating Income | 48.33% | 35.17% | |||
| Income Before Tax | 28.81% | 37.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.81% | 37.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.81% | 37.16% | |||
| EBIT | 48.33% | 35.17% | |||
| EBITDA | 50.09% | 38.66% | |||
| EPS Basic | 28.95% | 38.71% | |||
| Normalized Basic EPS | 26.09% | 41.03% | |||
| EPS Diluted | 28.95% | 38.71% | |||
| Normalized Diluted EPS | 26.09% | 41.03% | |||
| Average Basic Shares Outstanding | -0.32% | 3.88% | |||
| Average Diluted Shares Outstanding | -0.32% | 3.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||